Efficacy of liposomal bupivacaine in shoulder surgery: a systematic review and meta-analysis.
Analgesics, Opioid
/ therapeutic use
Anesthesia, Local
/ methods
Anesthetics, Local
/ administration & dosage
Arthroplasty, Replacement, Shoulder
/ adverse effects
Arthroscopy
/ adverse effects
Brachial Plexus Block
Bupivacaine
/ administration & dosage
Humans
Length of Stay
Liposomes
Pain Measurement
Pain, Postoperative
/ drug therapy
Rotator Cuff Injuries
/ surgery
Shoulder
/ surgery
Liposomal bupivacaine
interscalene nerve block
nonliposomal local anesthetics
opioids
reverse shoulder arthroplasty
rotator cuff repair
shoulder arthritis
total shoulder arthroplasty
Journal
Journal of shoulder and elbow surgery
ISSN: 1532-6500
Titre abrégé: J Shoulder Elbow Surg
Pays: United States
ID NLM: 9206499
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
01
2019
revised:
22
04
2019
accepted:
24
04
2019
pubmed:
22
7
2019
medline:
18
12
2019
entrez:
21
7
2019
Statut:
ppublish
Résumé
The aim of this meta-analysis was to compare the safety, efficacy, and opioid-sparing effect of liposomal bupivacaine (LB) vs. nonliposomal local anesthetic agents (NLAs) for postoperative analgesia after shoulder surgery. A systematic literature review of randomized controlled clinical studies comparing the efficacy of LB with NLAs in shoulder surgery was conducted. Seven level I and II studies were included in the meta-analysis, and shoulder surgical procedures included arthroscopic rotator cuff repair and shoulder arthroplasty. Bias was assessed using The Cochrane Collaboration's tool. The primary outcome measures were visual analog scale pain scores and opioid consumption 24 and 48 hours after shoulder surgery. Subgroup analysis was performed for the method of LB administration (interscalene nerve block vs. local infiltration). A total of 7 studies (535 patients) were included in the final meta-analysis comparing LB (n = 260) with NLAs (n = 275). No significant difference was found between the LB and NLA groups in terms of visual analog scale pain scores at 24 hours (95% confidence interval, -1.02 to 0.84; P = .86) and 48 hours (95% confidence interval, -0.53 to 0.71; P = .78). Both groups had comparable opioid consumption at both 24 hours (P = .43) and 48 hours (P = .78) postoperatively and with respect to length of stay (P = .87) and adverse events (P = .97). Subgroup analysis demonstrated comparable efficacy irrespective of the method of administration of LB. LB is comparable to NLAs with respect to pain relief, the opioid-sparing effect, and adverse effects in the first 48 hours after arthroscopic rotator cuff repair and total shoulder arthroplasty.
Identifiants
pubmed: 31324503
pii: S1058-2746(19)30324-6
doi: 10.1016/j.jse.2019.04.054
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Anesthetics, Local
0
Liposomes
0
Bupivacaine
Y8335394RO
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1824-1834Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.